Beijing Tiantan Biological Products Corp Ltd (600161) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Beijing Tiantan Biological Products Corp Ltd stock ¥5.60, price ¥12.67, that is 55.8% below the price, quality 44 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range ¥11.41 – ¥30.69 · fair‑value band ¥5.11 – ¥8.03 · the ¥12.67 price screens above the ¥5.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Beijing Tiantan Biological Products Corp in your weekly email
Every Wednesday you see whether Beijing Tiantan Biological Products Corp is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally.
Show moreShow less
Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products.
The company was founded in 1966 and is headquartered in Beijing, China.
Stock analysis
Beijing Tiantan Biological Products Corp Ltd (600161) currently trades at ¥12.67, while our model-based Fair Value estimate is ¥5.60, 56% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥12.98 per share, and 3 of the 17 models we run sit above the ¥12.67 price.
Bear case: the Asset-Based group reads lowest at ¥2.84, and 14 of the 17 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥5.11 (bear) to ¥8.03 (bull), the price of ¥12.67 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Beijing Tiantan Biological Products Corp Ltd reported revenue of 6.1B CNY in FY2025 versus 4.1B CNY in FY2021, a compound +10.5%/yr. Reported net income was 1.1B CNY in FY2025, compounding +9.5%/yr from FY2021.
Key figures
Market cap 25.1B CNY (≈ $3.8B) Mid · P/E ratio 35.2 · P/S ratio 6.16 · EPS (TTM) ¥0.3600 · Dividend yield 0.4% · Net margin 12.6% · Return on equity 6.3% · Return on assets (EBIT) 12.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −56%, 600161 screens richer than that median.
Fair Value models
Bear¥5.11Fair Value ¥5.60Bull¥8.03
Price ¥12.67 · Downside -55.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.2650 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.59/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
Start year 2020 (pandemic). Over 10 years: +14.3% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.4%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 5.4% / 20.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.32% → 29%
Compare Beijing Tiantan Biological Products Corp Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Above median
Fair Value upside−55.8% · Below median
Profitability
Return on equity (12 months)6.3% · Top 25%
Return on assets9.0% · Top 25%
Net margin (12 months)17.2% · Above median
Operating margin (12 months)21.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−7.2% · Below median
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)35.2× · Pricier than median
P/B2.13× · Pricier than median
P/S (12 months)6.16× · Pricier than median
EV/EBITDA19.3× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)25· sector 0
HEALTH (low debt)99· sector 97
DIVIDEND (yield)8· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Beijing Tiantan Biological Products Corp Ltd (600161) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of ¥5.60 versus a price of ¥12.67, about 56% lower (overvalued).
What is the fair value of 600161?
Our model-based fair value for Beijing Tiantan Biological Products Corp Ltd is ¥5.60 (as of Nov 3, 2026), built from audited fundamentals. The current price: ¥12.67.
What is the quality score of 600161?
Beijing Tiantan Biological Products Corp Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Tiantan Biological Products Corp Ltd (600161)?
Our model-based price target is the fair value of ¥5.60 (as of Nov 3, 2026) from 17 valuation models. Cautious scenario ¥5.11, optimistic scenario ¥8.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing Tiantan Biological Products Corp Ltd stock forecast for 2026?
Our models put fair value at ¥5.60, about 56% lower versus a price of ¥12.67 (overvalued). Cautious scenario ¥5.11, optimistic scenario ¥8.03. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Tiantan Biological Products Corp Ltd (600161)?
Beijing Tiantan Biological Products Corp Ltd reported trailing-twelve-month revenue of about 5.6B CNY (latest available figure, as of Nov 3, 2026).
Does Beijing Tiantan Biological Products Corp Ltd pay a dividend?
Beijing Tiantan Biological Products Corp Ltd currently shows a dividend yield of 0.39% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Beijing Tiantan Biological Products Corp Ltd (600161) and when is the ex-dividend date?
Beijing Tiantan Biological Products Corp Ltd pays a dividend of ¥0.05 per share a year, a dividend yield of 0.4%. The last ex-dividend date was Sep 23, 2026. The payout ratio is 13.9% of earnings. Our assessment: Token dividend. At a yield of 0.4% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.4% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Beijing Tiantan Biological Products Corp Ltd (600161)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Tiantan Biological Products Corp Ltd it is ¥5.60 per share (as of Nov 3, 2026), against a price of ¥12.67. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Beijing Tiantan Biological Products Corp Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 600161 trades above its calculated fair value: price ¥12.67, fair value ¥5.60, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600161?
No. The price is what the market pays today (¥12.67); the fair value is what the company's own numbers justify (¥5.60). For Beijing Tiantan Biological Products Corp Ltd the two are ¥7.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Tiantan Biological Products Corp Ltd worth?
The market values Beijing Tiantan Biological Products Corp Ltd at about 25.1B CNY (market capitalisation, as of Nov 3, 2026). Per share that is ¥12.67; our models calculate a fair value of ¥5.60 per share.
What do the bullish and bearish scenarios say about 600161?
Our models span a range for Beijing Tiantan Biological Products Corp Ltd: cautious scenario ¥5.11, base ¥5.60, optimistic ¥8.03 per share (as of Nov 3, 2026, price ¥12.67). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 600161?
Beijing Tiantan Biological Products Corp Ltd trades at a price-to-earnings ratio of 35.2 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥5.60 is built from several models across several years. Other multiples: P/B 2.1, P/S 6.2, EV/EBITDA 19.3.
How solid is the balance sheet of Beijing Tiantan Biological Products Corp Ltd (600161)?
Balance-sheet figures for Beijing Tiantan Biological Products Corp Ltd (as of Nov 3, 2026): return on equity 6.3%, debt of 0.02 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 600161 from its 52-week high?
Beijing Tiantan Biological Products Corp Ltd trades at ¥12.67, about 32% below its 52-week high of ¥18.64 and 11% above the low of ¥11.41 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥5.60 is for.
Which stocks are comparable to Beijing Tiantan Biological Products Corp Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Tiantan Biological Products Corp Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price ¥12.67, calculated fair value ¥5.60 (−56%), Quality Score 44/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600161 calculated?
We run Beijing Tiantan Biological Products Corp Ltd through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥5.60 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Beijing Tiantan Biological Products Corp Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Tiantan Biological Products Corp Ltd (600161)?
The closing price on Nov 6, 2026 was ¥12.67. Our model-based fair value is ¥5.60, about 56% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Tiantan Biological Products Corp Ltd right now?
The price sits above even our optimistic bull case (¥8.03). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
Where does the earnings growth of Beijing Tiantan Biological Products Corp Ltd (600161) come from?
Earnings per share at Beijing Tiantan Biological Products Corp Ltd grew +24.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.9 %, EBIT margin +10.3 %, tax rate +2.4 %, residual (interest, one-offs) +0.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Beijing Tiantan Biological Products Corp Ltd
How large is the market capitalisation of Beijing Tiantan Biological Products Corp Ltd (600161)?
The market capitalisation of Beijing Tiantan Biological Products Corp Ltd is 25.1B CNY (≈ $3.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Tiantan Biological Products Corp Ltd (600161)?
The price-to-sales ratio of Beijing Tiantan Biological Products Corp Ltd is 6.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beijing Tiantan Biological Products Corp Ltd (600161)?
Earnings per share at Beijing Tiantan Biological Products Corp Ltd are ¥0.3600 (price ÷ EPS = P/E 35.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Beijing Tiantan Biological Products Corp Ltd (600161)?
The dividend yield of Beijing Tiantan Biological Products Corp Ltd is 0.4% (payout 13.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Beijing Tiantan Biological Products Corp Ltd (600161)?
The net margin of Beijing Tiantan Biological Products Corp Ltd is 12.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing Tiantan Biological Products Corp Ltd (600161)?
The return on equity (ROE) of Beijing Tiantan Biological Products Corp Ltd is 6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Tiantan Biological Products Corp Ltd (600161)?
On an EBIT basis the return on assets of Beijing Tiantan Biological Products Corp Ltd is 12.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Tiantan Biological Products Corp Ltd (600161)?
The operating margin of Beijing Tiantan Biological Products Corp Ltd is 21.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Tiantan Biological Products Corp Ltd (600161)?
Revenue at Beijing Tiantan Biological Products Corp Ltd is growing −7.2% versus a year earlier (3y avg +12.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beijing Tiantan Biological Products Corp Ltd (600161)?
Earnings per share at Beijing Tiantan Biological Products Corp Ltd are growing −23.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Beijing Tiantan Biological Products Corp Ltd (600161) generate?
The free cash flow of Beijing Tiantan Biological Products Corp Ltd is −230M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Beijing Tiantan Biological Products Corp Ltd (600161) hold?
Beijing Tiantan Biological Products Corp Ltd holds more cash than debt, 1.8B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Beijing Tiantan Biological Products Corp Ltd in the live analysis
One click puts Beijing Tiantan Biological Products Corp Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026